Case Report: Nasal swelling and ulceration as a unique immune-related cutaneous adverse event of atezolizumab in small cell lung cancer - Takeaways - MDSpire

Case Report: Nasal swelling and ulceration as a unique immune-related cutaneous adverse event of atezolizumab in small cell lung cancer

  • By

  • Junhui Yang

  • Xuemei Du

  • Hongyun Liu

  • Yueqin Hao

  • April 30, 2026

  • 0 min

Share

  • 1

    Atezolizumab treatment in a patient with small cell lung cancer led to rare immune-related cutaneous adverse events, specifically nasal swelling and ulceration.

  • 2

    The patient, a 56-year-old male, experienced worsening nasal symptoms despite discontinuing anlotinib and receiving broad-spectrum antimicrobial therapy.

  • 3

    Histopathological analysis ruled out metastatic carcinoma and other infectious or autoimmune causes, confirming the adverse reaction was likely due to atezolizumab.

  • 4

    Discontinuation of atezolizumab and administration of glucocorticoids resulted in significant improvement of the patient's nasal skin condition.

  • 5

    This case highlights the importance of recognizing rare immune-related cutaneous adverse events to prevent misdiagnosis and mistreatment in cancer patients.

Original Source(s)

Case Report: Nasal swelling and ulceration as a unique immune-related cutaneous adverse event of atezolizumab in small cell lung cancer

  • by Junhui Yang, Xuemei Du, Hongyun Liu, Yueqin Hao

  • April 30, 2026

Related Content

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III